HCA
NTLA icon

Heck Capital Advisors’s Intellia Therapeutics NTLA Stock Holding History

Heck Capital Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25
Closed -$291 – 608
2024
Q4 		$291 Buy
+25
New +$390 ﹤0.01% 773

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Heck Capital Advisors's NTLA Position: Q1 2025 in Review

Heck Capital Advisors sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 25 shares — an estimated $291 sold.

Heck Capital Advisors first reported a position in NTLA in Q4 2024 and held it in 1 quarter. The position peaked at $291 in Q4 2024. 295 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

  • Heck Capital Advisors reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Heck Capital Advisors sold 25 Intellia Therapeutics shares in Q1 2025, an estimated $291.
  • Heck Capital Advisors first reported a position in Intellia Therapeutics in Q4 2024 and held it in 1 quarter.
  • Heck Capital Advisors's Intellia Therapeutics position peaked at $291 in Q4 2024.
  • 295 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Heck Capital Advisors's 13F filing for Q1 2025, filed 13 May 2025.